Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023

BUY
$1.97 - $3.69 $120,672 - $226,030
61,255 Added 98.14%
123,669 $397 Million
Q1 2023

May 10, 2023

BUY
$2.14 - $3.4 $133,565 - $212,207
62,414 New
62,414 $135 Million

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.34B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Innovis Asset Management LLC Portfolio

Follow Innovis Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Innovis Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Innovis Asset Management LLC with notifications on news.